Amylyx to stop development of rare brain disorder drug after trial failure
27/08/2025 12:09
Aug 27 (Reuters) - Amylyx Pharmaceuticals AMLX.O said on Wednesday it will discontinue development of its experimental drug for a rare brain disorder after the treatment failed to show benefit in a mid-stage trial. (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock